Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
PLoS Biol ; 22(2): e3002502, 2024 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-38421949

RESUMO

Peer review is an important part of the scientific process, but traditional peer review at journals is coming under increased scrutiny for its inefficiency and lack of transparency. As preprints become more widely used and accepted, they raise the possibility of rethinking the peer-review process. Preprints are enabling new forms of peer review that have the potential to be more thorough, inclusive, and collegial than traditional journal peer review, and to thus fundamentally shift the culture of peer review toward constructive collaboration. In this Consensus View, we make a call to action to stakeholders in the community to accelerate the growing momentum of preprint sharing and provide recommendations to empower researchers to provide open and constructive peer review for preprints.


Assuntos
Revisão por Pares , Pesquisadores , Humanos , Movimento (Física)
2.
Curr Protoc Mol Biol ; Chapter 14: Unit14.20, 2010 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-20890901

RESUMO

With the advent of digital cameras and motorization of mechanical components, computer control of microscopes has become increasingly important. Software for microscope image acquisition should not only be easy to use, but also enable and encourage novel approaches. The open-source software package µManager aims to fulfill those goals. This unit provides step-by-step protocols describing how to get started working with µManager, as well as some starting points for advanced use of the software.


Assuntos
Automação/métodos , Computadores , Microscopia/métodos , Software
3.
J Biol Chem ; 282(48): 34748-57, 2007 Nov 30.
Artigo em Inglês | MEDLINE | ID: mdl-17911103

RESUMO

Alefacept is a chimeric protein combining CD58 immunoglobulin-like domain 1 with human IgG1 Fc. Alefacept mediates adhesion by bridging CD2 on T cells to activating Fc receptors on effector cells, but the equilibrium binding parameters have not been determined. Alefacept mediated T cell killing by NK cells and adhesion between CD2- and CD16-expressing cells at an optimum concentration of 100 nM. We introduce novel measurements with supported planer bilayers, from which key two-dimensional and three-dimensional parameters can be determined by data fitting. Alefacept competitively inhibited cell bilayer adhesion mediated by the CD2-CD58 interaction. Alefacept mediated maximal adhesion of CD2(+) T cells to CD16B, an Fc receptor, in planar bilayers at 500 nM. A mechanistic model for alefacept-mediated cell-bilayer adhesion allowed fitting of the data and determination of two-dimensional binding parameters. These included the density of bonds in the adhesion area, which grew to maintain a consistent average bond density of 200 molecules/microm(2) and two-dimensional association constants of 3.1 and 630 microm(2) for bivalently and monovalently bound forms of alefacept, respectively. The maximum number of CD16 bound and the fit value of 4,350 CD2 per cell are much lower than the 40,000 CD2 per cell measured with anti-CD2 Fab. These results suggest that additional information is needed to correctly predict Alefacept-mediated bridge formation.


Assuntos
Antígenos CD2/biossíntese , Antígenos CD58/química , Receptores de IgG/biossíntese , Proteínas Recombinantes de Fusão/química , Alefacept , Animais , Células CHO , Adesão Celular , Cricetinae , Cricetulus , Fármacos Dermatológicos/química , Fármacos Dermatológicos/farmacologia , Relação Dose-Resposta a Droga , Humanos , Células Jurkat , Cinética , Bicamadas Lipídicas/química , Ligação Proteica , Receptores Fc/química , Receptores de IgG/química , Proteínas Recombinantes de Fusão/farmacologia , Linfócitos T/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...